The National Center for Advancing Translational Sciences (NCATS) Tissue Chip for Drug Screening program represents the largest federal investment in microphysiological systems. Launched in 2012, the program has invested over $200 million to develop, validate, and commercialize human tissue chip technology for predicting drug safety and efficacy.
PROGRAM PHASES
Phase I (2012-2014): Initial tissue chip development - 17 projects funded
Phase II (2014-2017): Integration and validation - Multi-organ systems
Phase IIB (2017-2022): Clinical validation and disease modeling
Phase III (2022-present): Regulatory qualification and commercialization
KEY ACHIEVEMENTS
Developed functional chips for 15+ organ systems
ISS National Lab experiments validating space-based tissue chips
FDA collaboration for regulatory pathway development
Multiple commercial spin-offs from funded research
Published>500 peer-reviewed papers from program research
PARTNER INSTITUTIONS
Major research centers include MIT, Harvard/Wyss Institute, University of Washington, University of Pittsburgh, Vanderbilt University, and Lawrence Livermore National Laboratory.
The National Institutes of Health (NIH) has been at the forefront of transforming how we develop and test new therapeutics. Through the National Center for Advancing Translational Sciences (NCATS), the NIH has invested over $200 million in the Tissue Chip for Drug Screening program since 2012, making it the largest federal initiative dedicated to advancing organ-on-chip technology and microphysiological systems (MPS).
Bridging the Translational Gap
Traditional drug development suffers from a 90% failure rate when translating preclinical animal results to human clinical trials. NCATS recognized that human-relevant testing platforms could dramatically improve this translation, reducing costly late-stage failures and accelerating patient access to life-saving therapies.
De-Risking Innovation
By funding early-stage research that commercial entities cannot justify, NIH enables breakthrough technologies to reach maturity. The Tissue Chip program provides the validation data and regulatory groundwork that pharmaceutical companies need before adopting new testing methods at scale.
Public-Private Partnerships
NCATS has pioneered collaborative models bringing together academia, pharmaceutical companies, regulatory agencies, and technology developers. These partnerships ensure that tissue chips meet real-world needs and can be integrated into existing drug development workflows.
Regulatory Pathway Development
Working closely with FDA, NCATS has helped establish qualification pathways for tissue chip technologies. This collaboration ensures that validated platforms can be confidently used in regulatory submissions, enabling the FDA Modernization Act 2.0 to have practical impact.
NCATS Tissue Chip Impact by the Numbers
$200M+
Total Investment
70+
Research Projects
15+
Organ Systems
500+
Publications
12+
Commercial Spinoffs
25+
Partner Institutions
The NCATS Tissue Chip program represents a paradigm shift in how government funding can accelerate the adoption of transformative technologies. By focusing on validation, standardization, and regulatory acceptance, NIH has created an ecosystem where academic innovations can rapidly translate into tools that improve drug development for patients worldwide.
NCATS Tissue Chip Program Milestones
Year
Phase/Milestone
Key Achievements
Funding
2012
Phase I Launch
17 research teams funded to develop initial tissue chip prototypes for liver, heart, lung, kidney, and brain
$70M
2014
Phase II Integration
Multi-organ chip development begins; first tissue chips sent to International Space Station
$37M
2016
FDA Collaboration
Formal partnership with FDA established; liver chip validation studies initiated with reference compounds
Machine learning models trained on tissue chip data; predictive toxicology algorithms developed
$18M
2025
Body-on-Chip Systems
10-organ interconnected systems; patient avatar development; precision medicine applications
$22M
Key NCATS-Funded Research Centers
Wyss Institute / Harvard University
Pioneered the organ-on-chip concept; developed lung, gut, kidney, and bone marrow chips. Technology licensed to Emulate Inc., now used by top pharma companies worldwide.
Focus: Lung-on-chip, Gut-on-chip, Multi-organ systems
MIT / Koch Institute
Developed advanced microfluidic platforms and liver chip systems. Leading work on physiologically-based pharmacokinetic (PBPK) integration and computational modeling.
Focus: Liver chips, PBPK modeling, Drug metabolism
University of Pittsburgh
Specializes in liver and multi-organ systems with integrated biosensors. Key contributor to drug-induced liver injury (DILI) prediction and metabolic modeling.
Focus: DILI prediction, Biosensor integration, Liver-kidney crosstalk
University of Washington
Leading kidney chip development with functional filtration and tubular transport. Working on nephrotoxicity prediction and kidney disease modeling.
Focus: Kidney-on-chip, Nephrotoxicity, Proximal tubule function
Vanderbilt University
Developed heart-on-chip systems measuring contractility and electrophysiology. Key work on cardiotoxicity prediction and arrhythmia modeling.
What is the NCATS Tissue Chip for Drug Screening program?
The NCATS Tissue Chip for Drug Screening program is a multi-phase NIH initiative launched in 2012 to develop, validate, and commercialize human tissue chip (organ-on-chip) technology. With over $200 million invested, the program funds academic and industry teams creating microphysiological systems that replicate human organ function for predicting drug safety and efficacy. The goal is to reduce drug development failures, lower costs, and decrease reliance on animal testing by providing more human-relevant preclinical data.
How can researchers apply for NCATS Tissue Chip funding?
NCATS issues Funding Opportunity Announcements (FOAs) through the NIH Guide for Grants and Contracts. Researchers at academic institutions, non-profits, and small businesses can apply through the standard NIH grant process (R01, R21, U01, SBIR/STTR mechanisms). Applications are reviewed for scientific merit, innovation, and alignment with program goals. NCATS also hosts workshops and webinars explaining current priorities. Prospective applicants should contact NCATS program staff to discuss project fit before submitting. Current opportunities focus on validation studies, multi-organ integration, and regulatory-ready platforms.
What is the Tissue Chip Testing Center and how does it work?
The NCATS Tissue Chip Testing Centers (TCTCs) are centralized facilities that conduct independent, standardized evaluation of tissue chip platforms. Chip developers submit their systems along with protocols, and TCTC staff test them using reference compound libraries with known human toxicities. This provides unbiased performance data comparing chip predictions to clinical outcomes. Results help identify which platforms are ready for pharmaceutical adoption and generate validation packages supporting regulatory submissions. The TCTC model ensures reproducibility across different laboratories and builds confidence in tissue chip technology.
How does NCATS collaborate with the FDA on tissue chip acceptance?
NCATS and FDA have a formal collaboration agreement to advance tissue chip regulatory acceptance. Joint activities include: defining performance benchmarks and qualification criteria; conducting validation studies using FDA-relevant toxicity endpoints; training FDA reviewers on interpreting tissue chip data; developing guidance documents for industry; and hosting joint workshops bringing together chip developers, pharma sponsors, and regulators. This collaboration ensures that NCATS-funded platforms generate data that FDA can confidently accept in regulatory submissions, making the FDA Modernization Act 2.0 practically implementable.
What organ systems has the NCATS program developed chips for?
NCATS has funded development of tissue chips for over 15 organ systems including: liver (hepatotoxicity, drug metabolism), heart (cardiotoxicity, arrhythmias), kidney (nephrotoxicity, filtration), lung (respiratory toxicity, inflammation), brain (blood-brain barrier, neurotoxicity), gut (absorption, microbiome), skin (dermal toxicity, wound healing), bone marrow (hematotoxicity), pancreas (diabetes modeling), eye (retinal toxicity), placenta (maternal-fetal transfer), muscle (myotoxicity), fat (metabolic disease), blood vessels (vascular function), and lymph nodes (immune response). Multi-organ systems linking 4-10 chips are now in development.
What role does the IQ MPS Consortium play in the NCATS program?
The IQ MPS (Microphysiological Systems) Affiliate is a consortium of major pharmaceutical companies that partners with NCATS to evaluate tissue chip platforms for industrial drug development. Member companies (including Pfizer, Merck, Roche, J&J, and others) test NCATS-funded chips with their proprietary compounds, sharing learnings on performance and identifying gaps. This pharma perspective ensures that tissue chips meet real-world needs for throughput, reproducibility, and data quality. The consortium also develops best practices, standardization protocols, and training materials that accelerate industry adoption of validated platforms.
How has the NCATS program contributed to COVID-19 research?
During the COVID-19 pandemic, NCATS rapidly deployed tissue chip technology for SARS-CoV-2 research. Lung chips with primary human alveolar cells modeled viral infection and inflammatory responses. Vascular chips studied endothelial dysfunction and clotting. Multi-organ systems assessed systemic effects. Chips were used to screen approved drugs for repurposing, identifying candidates faster than traditional methods. NCATS-funded teams published key findings on viral mechanisms and therapeutic targets. The pandemic demonstrated tissue chips' value for rapid response to emerging threats, informing preparedness planning for future outbreaks.
What are the current priorities and future directions for the NCATS program?
Current NCATS priorities include: body-on-chip systems linking 10+ organs for systemic toxicity prediction; patient-specific chips using iPSCs for precision medicine and clinical trial matching; integration with AI/ML for predictive modeling and data analysis; vascularized chips enabling immune cell trafficking and inflammation studies; standardized protocols and quality metrics for regulatory acceptance; automation and high-throughput scaling for pharma adoption; and specialized platforms for rare diseases, pediatric populations, and sex-specific responses. The ultimate vision is "patient avatars" that can predict individual drug responses before clinical exposure.
Frequently Asked Questions
NCATS (National Center for Advancing Translational Sciences) Tissue Chip Program funds development of organ-on-chip technology for drug development. Since 2012, it has invested $200+ million advancing MPS science and applications.
The program developed chips for 15+ organ systems, tested drugs on the International Space Station, advanced disease models for COVID-19 and rare diseases, and supported commercial translation of academic innovations.
Testing Centers are core facilities providing standardized tissue chip testing services to researchers. They ensure quality control and enable consistent validation across the field.
NCATS and FDA collaborate through the Tissue Chip program, co-funding projects demonstrating regulatory utility. This partnership aligns technology development with regulatory acceptance requirements.
This initiative supports development of multi-organ systems for preclinical drug testing. Current projects create linked liver-kidney-heart-lung systems mimicking human drug responses.
The regulatory landscape for alternative testing methods has evolved significantly since the 3Rs principles were first established by Russell and Burch in 1959. Modern pharmaceutical development increasingly relies on human-relevant testing platforms including organ-on-chip systems, patient-derived organoids, computational PBPK models, and high-throughput transcriptomics. These New Approach Methodologies offer superior prediction of human clinical outcomes compared to traditional animal models, with studies demonstrating 87% concordance versus 43% for animal tests. Regulatory agencies globally have established qualification pathways allowing sponsors to gain confidence in method acceptance before conducting expensive validation studies. The integration of NAMs into drug development programs reduces costs, accelerates timelines, and importantly provides mechanistic insights at cellular and molecular resolution impossible in whole animal experiments.
Traditional vs. New Approach Methodologies
Aspect
Animal Testing
Organ-on-Chip / NAMs
Human Relevance
Species differences cause 90% failure rate in translating animal results to humans
Uses human cells and tissues, directly predicting human responses
Timeline
18-24 months for preclinical animal studies
2-8 weeks for organ chip validation
Cost per Test
$10,000-$50,000 per animal study
$500-$5,000 per chip experiment
Throughput
Limited by animal housing, breeding, and care requirements
High-throughput screening of hundreds of compounds simultaneously
Ethical Concerns
Involves suffering and sacrifice of millions of animals annually
No animal use, aligns with 3Rs principles
Regulatory Status
Traditional requirement, but no longer mandatory under FDA Modernization Act 2.0
Increasingly accepted by FDA, EMA, and OECD for regulatory submissions
Personalization
Inbred strains, cannot model human genetic diversity
Patient-derived cells enable precision medicine approaches
NCATS (National Center for Advancing Translational Sciences) Tissue Chip for Drug Screening program is NIH initiative funding development and validation of microphysiological systems that model human organs for toxicity testing and efficacy prediction without animal use.
When did NCATS start the Tissue Chip program?
NCATS launched Tissue Chip program in 2011 with $70 million initial funding. The program evolved from earlier NIH Microphysiological Systems initiative and has awarded over $250 million to academic and industry teams developing organ chip platforms over past decade.
What organ chips has NCATS funded?
NCATS has funded liver chips from multiple institutions, heart chips modeling contractility and electrical activity, kidney chips with filtration barriers, lung chips with breathing motion and air-liquid interface, brain chips with blood-brain barrier, gut chips with microbiome, and multi-organ systems linking multiple tissues.
How does NCATS validation work?
NCATS validation involves testing organ chips with libraries of reference compounds having known human toxicities, comparing chip predictions to clinical outcomes, conducting reproducibility studies across laboratories, establishing performance benchmarks, and publishing results enabling regulatory acceptance.
What is the Tissue Chip Testing Center?
NCATS established centralized testing facilities where validated organ chips undergo standardized evaluation with reference compound libraries. Centers provide unbiased assessment of platform performance, generate data supporting regulatory submissions, and identify platforms ready for pharmaceutical adoption.
Can pharmaceutical companies access NCATS organ chips?
Yes. NCATS encourages technology transfer and many funded platforms are commercially available through companies like Emulate, CN Bio, and TissUse. NCATS also facilitates partnerships connecting chip developers with pharma companies for validation studies and drug development applications.
What challenges has NCATS identified?
Key challenges include achieving tissue maturity matching adult human organs, maintaining long-term culture for chronic toxicity testing, standardizing platforms for reproducible results across sites, scaling throughput for drug screening, and demonstrating superior performance versus animal models for regulatory acceptance.
How does NCATS support FDA acceptance?
NCATS conducts validation studies using FDA-relevant endpoints, generates data packages demonstrating predictive accuracy, collaborates with FDA reviewers on platform evaluation, funds regulatory science research addressing FDA questions, and facilitates meetings between chip developers and agency scientists.
What is the IQ MPS Affiliate and how does it relate to NCATS?
IQ MPS Affiliate is pharmaceutical industry consortium that partners with NCATS to evaluate organ chip platforms for drug development. Member companies test chips with proprietary compounds, share learnings on best practices, and provide pharma perspective on what capabilities are needed for adoption.
What future directions is NCATS pursuing?
Future directions include body-on-chip systems linking multiple organs, patient-specific chips using iPSCs for precision medicine, integration with AI for predictions, vascularized chips enabling immune cell trafficking, and standardized protocols allowing regulatory acceptance for specific safety endpoints.